Cargando…
Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study
BACKGROUND: Treatment options are limited for recurrent/metastatic adenoid cystic carcinoma of the head and neck (R/M ACCHN). We aimed to evaluate the preliminary results of the efficacy and safety of all‐trans retinoic acid (ATRA) combined with low‐dose apatinib in patients with R/M ACCHN according...
Autores principales: | Ye, Lulu, Zhang, Lin, Li, Rongrong, Pan, Xinhua, Li, Jiang, Dou, Shengjin, Jiang, Wen, Wang, Chong, Chen, Wantao, Zhu, Guopei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166967/ https://www.ncbi.nlm.nih.gov/pubmed/36734294 http://dx.doi.org/10.1002/cam4.5653 |
Ejemplares similares
-
Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
por: Zhu, Guopei, et al.
Publicado: (2021) -
The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication
por: Dou, Shengjin, et al.
Publicado: (2021) -
Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial
por: Jiang, Wen, et al.
Publicado: (2023) -
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
por: Dou, Shengjin, et al.
Publicado: (2022) -
Long‐term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study
por: Dou, Shengjin, et al.
Publicado: (2020)